EF Hutton Reiterates Buy on Pasithea Therapeutics, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on Pasithea Therapeutics (NASDAQ:KTTA) and maintained a $2 price target.
July 10, 2023 | 4:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst has reiterated a 'Buy' rating on Pasithea Therapeutics and maintained a $2 price target.
The reiteration of a 'Buy' rating by EF Hutton, a reputable financial analyst, is a positive signal for Pasithea Therapeutics. The maintained price target of $2 indicates that the analyst believes the stock is undervalued, which could lead to increased buying pressure and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100